SecBot SecBot
425 ·Filed May 19, 2026

INM

InMed Pharmaceuticals Inc.
MIXED
Impact 7/10
Horizonweeks Processed6mo ago SEC0001213900-26-058800
Rule 425 M&A communications
Actionable Insight ◆ Mixed

Monitor shareholder votes and SEC effectiveness. The deal's success hinges on the $150M PIPE closing. If approved, INM stock will effectively represent a small fraction of the combined entity. Traders should consider the massive dilution and potential upside from the PIPE-funded pipeline.

DirectionMixed
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.60
T+0 close · May 19, 2026 · via day close
Latest settled
−10.63%
T+60 · $1.43
Vs SPY
−16.92%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 19 $1.60entry
  2. T+1 · 6mo ago +0.63%α −0.41% · $1.61
  3. T+5 · 6mo ago +5.63%α +3.38% · $1.69
  4. T+20 · 5mo ago −6.88%α −7.86% · $1.49
  5. T+60 · 3mo ago −10.63%α −16.92% · $1.43
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

InMed Pharmaceuticals (INM) entered into a definitive reverse merger agreement with Mentari Therapeutics, where Mentari shareholders will receive a majority stake in the combined entity. A concurrent PIPE of at least $150 million will fund operations. Existing INM shareholders face massive dilution but receive contingent value rights. The deal transforms the company but substantially dilutes current holders.

Key Financial Metrics

Deal Type
merger

Key Facts

  • Reverse merger: Mentari Therapeutics merges with INM via a two-step process, with Mentari shareholders receiving majority ownership.
  • Concurrent PIPE of at least $150 million from investors, including conversion of existing convertible notes.
  • INM shareholders receive contingent value rights (CVRs) for future payments.
  • Mentari equity value set at $125 million (excluding PIPE proceeds), with INM parent valuation capped at $10 million.
  • Net cash adjustment formula for INM potentially reduces its valuation, with a base of negative $3.4 million.
  • Deal subject to shareholder approvals, SEC registration, Nasdaq listing, and other conditions.
  • Termination fee of $400,000 if INM takes a superior offer, and $4 million if Mentari fails to close.

Financial Impact

PIPE of at least $150 million; post-merger entity valuation implied in hundreds of millions, but existing INM shareholders heavily diluted.

dilutioncashvaluationownership structure

Risk Factors

  • Failure to raise minimum PIPE amount ($150M) could kill the deal.
  • Regulatory or shareholder approval delays or denials.
  • Massive dilution for existing INM shareholders reduces per-share value.
  • Integration risks and execution of Mentari's pipeline.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
425 Filing (Primary)0001213900-26-058800
Document: ea029148201ex10-5.htm0001213900-26-058800
Document: ea029148201ex10-4.htm0001213900-26-058800

US Market Status

Market Closed · Opens in 6h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 19, 2026